Markus Reindl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8529947/publications.pdf

Version: 2024-02-01

143 papers	13,704 citations	34100 52 h-index	22161 113 g-index
146 all docs	146 docs citations	146 times ranked	8139 citing authors

#	Article	IF	Citations
1	Reply to â€œInvestigating the Immunopathogenic Mechanisms Underlying <scp>MOGAD</scp>â€. Annals of Neurology, 2022, 91, 300-301.	5.3	2
2	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology, 2022, 149, 1242-1252.e12.	2.9	23
3	Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. Multiple Sclerosis Journal, 2022, 28, 1553-1561.	3.0	20
4	Guilty by association? SARSâ€CoVâ€2 antibodies and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. European Journal of Neurology, 2022, , .	3.3	1
5	MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. Acta Neuropathologica, 2021, 141, 127-131.	7.7	21
6	Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathologica, 2021, 141, 801-804.	7.7	14
7	German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosis. BMC Neurology, 2021, 21, 163.	1.8	2
8	Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110227.	1.0	20
9	Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?. Journal of Neuroinflammation, 2021, 18, 121.	7.2	22
10	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	7.2	44
11	NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. Multiple Sclerosis and Related Disorders, 2021, 50, 102833.	2.0	15
12	Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study. Frontiers in Immunology, 2021, 12, 641106.	4.8	2
13	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
14	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 684014.	4.8	37
15	T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	18
16	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
17	Complement Activation Is a Prominent Feature of <scp>MOGAD</scp>. Annals of Neurology, 2021, 90, 976-982.	5.3	35
18	6-month SARS-CoV-2 antibody persistency in aÂTyrolian COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 351-358.	1.9	10

#	Article	IF	Citations
19	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. Frontiers in Immunology, 2021, 12, 769653.	4.8	3
20	Temporal Dynamics of MOG Antibodies in Children with Acquired Demyelinating Syndrome. Neuropediatrics, 2021, 52, .	0.6	2
21	12-month SARS-CoV-2 antibody persistency in aÂTyrolean COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 1265-1271.	1.9	2
22	Transient MOG antibody seroconversion associated with immunomodulating therapy. Multiple Sclerosis and Related Disorders, 2020, 37, 101420.	2.0	4
23	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. Journal of Child Neurology, 2020, 35, 77-83.	1.4	5
24	AQP4 autoantibodies in patients with idiopathic normal pressure hydrocephalus. Journal of Neuroimmunology, 2020, 349, 577407.	2.3	3
25	Presence of anti-neuronal antibodies in children with neurological disorders beyond encephalitis. European Journal of Paediatric Neurology, 2020, 28, 159-166.	1.6	4
26	Recent developments in MOG-IgG associated neurological disorders. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094513.	3.5	45
27	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. Journal of Neuroinflammation, 2020, 17, 262.	7.2	44
28	Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up. Journal of Neurology, 2020, 268, 2700-2702.	3.6	5
29	Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	67
30	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	2.0	110
31	Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	3
32	Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	15
33	Epidemiology of Pediatric NMOSD in Germany and Austria. Frontiers in Neurology, 2020, 11, 415.	2.4	10
34	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Frontiers in Immunology, 2020, 11, 1188.	4.8	16
35	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism and Related Disorders, 2020, 77, 57-63.	2.2	18
36	Teaching NeuroImages: Bilateral optic neuritis. Neurology, 2020, 95, e2045-e2046.	1.1	1

#	Article	IF	Citations
37	Cell-based assays for the detection of MOG antibodies: a comparative study. Journal of Neurology, 2020, 267, 3555-3564.	3.6	44
38	International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	180
39	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of Î±-synucleinopathy. Journal of Neuroinflammation, 2020, 17, 35.	7.2	11
40	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Acta Neuropathologica, 2020, 139, 547-564.	7.7	11
41	High association of MOG-IgG antibodies in children with bilateral optic neuritis. European Journal of Paediatric Neurology, 2020, 27, 86-93.	1.6	22
42	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes. Acta Neuropathologica Communications, 2020, 8, 49.	5.2	5
43	Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. Journal of Neuroinflammation, 2019, 16, 154.	7.2	61
44	Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology, 2019, 93, e1867-e1872.	1.1	80
45	Anti-thyroid autoantibodies as biomarkers for alemtuzumab associated thyroid autoimmunity. EBioMedicine, 2019, 47, 22-23.	6.1	2
46	Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731984846.	1.0	10
47	Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology, 2019, 92, 765-767.	1.1	30
48	Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1293-1296.	1.9	40
49	German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol. BMJ Open, 2019, 9, e029565.	1.9	3
50	Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology, 2019, 15, 89-102.	10.1	439
51	Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathologica, 2019, 137, 467-485.	7.7	56
52	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Multiple Sclerosis Journal, 2019, 25, 267-274.	3.0	29
53	Failure of Expected Brain Growth in Children with ADEM. , 2019, 50, .		0
54	New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. Multiple Sclerosis and Related Disorders, 2018, 22, 35-37.	2.0	11

#	Article	IF	Citations
55	Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Current Opinion in Neurology, 2018, 31, 325-333.	3.6	48
56	MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. Journal of Neurology, 2018, 265, 845-855.	3.6	68
57	Clinical course of MOG antibody-associated recurrent demyelinating diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 118-118.	1.9	4
58	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. Case Reports in Neurological Medicine, 2018, 2018, 1-3.	0.4	7
59	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. Parkinsonism and Related Disorders, 2017, 38, 102-103.	2.2	18
60	Prognostic value of free light chains lambda and kappa in early multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1496-1505.	3.0	34
61	Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology, 2017, 89, 207-209.	1.1	27
62	ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e335.	6.0	65
63	Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?. Current Opinion in Neurology, 2017, 30, 295-301.	3.6	92
64	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. Journal of Neurology, 2017, 264, 2420-2430.	3.6	120
65	Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology, 2017, 89, 900-908.	1.1	278
66	Discontinuation of disease-modifying therapies in multiple sclerosis â€“ Clinical outcome and prognostic factors. Multiple Sclerosis Journal, 2017, 23, 1241-1248.	3.0	56
67	Methodological Challenges in Protein Microarray and Immunohistochemistry for the Discovery of Novel Autoantibodies in Paediatric Acute Disseminated Encephalomyelitis. International Journal of Molecular Sciences, 2017, 18, 679.	4.1	5
68	Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Frontiers in Immunology, 2017, 8, 529.	4.8	184
69	CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1. Sleep, 2017, 40, .	1.1	27
70	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. PLoS ONE, 2017, 12, e0182462.	2.5	26
71	MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome. BMC Neurology, 2017, 17, 190.	1.8	21
72	Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. Journal of Neuroinflammation, 2017, 14, 208.	7.2	105

#	Article	IF	Citations
73	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Journal of the Neurological Sciences, 2017, 381, 240-244.	0.6	29
74	Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosisâ€"The PaSiMS II study. PLoS ONE, 2017, 12, e0181458.	2.5	2
75	Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS ONE, 2016, 11, e0158978.	2.5	56
76	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
77	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	1.8	13
78	Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathologica, 2016, 132, 43-58.	7.7	75
79	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	3.6	112
80	Age-Dependent Seroprevalence of JCV Antibody in Children. Neuropediatrics, 2016, 47, 112-114.	0.6	11
81	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. Multiple Sclerosis and Related Disorders, 2016, 9, 150-154.	2.0	11
82	Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroinflammation, 2016, 13, 176.	7.2	14
83	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation, 2016, 13, 279.	7.2	351
84	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, 280.	7.2	686
85	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation, 2016, 13, 282.	7.2	217
86	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation, 2016, 13, 281.	7.2	202
87	Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathologica Communications, 2016, 4, 82.	5.2	41
88	Widening the spectrum of autoantibodies in pediatric brainstem encephalitis. Developmental Medicine and Child Neurology, 2016, 58, 791-792.	2.1	0
89	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	1.9	89
90	Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination. Journal of Neuroimmunology, 2016, 290, 49-53.	2.3	15

#	Article	IF	Citations
91	Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 897-905.	1.9	98
92	Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Multiple Sclerosis Journal, 2016, 22, 1821-1829.	3.0	128
93	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in â€˜pattern II multiple sclerosisâ€™ and brain biopsy findings in a MOG-IgG-positive case. Multiple Sclerosis Journal, 2016, 22, 1541-1549.	3.0	96
94	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	10.2	2,782
95	Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3323-3328.	7.1	105
96	Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord. PLoS ONE, 2016, 11, e0151244.	2.5	15
97	Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	7
98	Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Reports, 2015, 2015, bcr2014209075-bcr2014209075.	0.5	7
99	MOG antibody-associated diseases. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e60.	6.0	66
100	Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e131.	6.0	98
101	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathologica, 2015, 130, 783-798.	7.7	55
102	Fulminant demyelinating encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e175.	6.0	75
103	Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. Multiple Sclerosis Journal, 2015, 21, 651-655.	3.0	9
104	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	6.0	322
105	Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e160.	6.0	13
106	Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Journal of Neuroimmunology, 2015, 287, 98-105.	2.3	8
107	NMDA receptor antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e141.	6.0	44
108	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	3.0	241

#	Article	IF	Citations
109	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. PLoS ONE, 2015, 10, e0122037.	2.5	27
110	Immunohistochemistry. , 2015, , 143-158.		1
111	Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics. Journal of Neuroimmunology, 2014, 277, 145-152.	2.3	5
112	Overlapping demyelinating syndromes and antiâ€"Nâ€methylâ€Dâ€aspartate receptor encephalitis. Annals of Neurology, 2014, 75, 411-428.	5.3	405
113	Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathologica Communications, 2013, 1, 5.	5.2	52
114	T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathologica Communications, 2013, 1, 85.	5.2	73
115	The spectrum of MOG autoantibody-associated demyelinating diseases. Nature Reviews Neurology, 2013, 9, 455-461.	10.1	330
116	Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. Journal of the Neurological Sciences, 2013, 328, 77-82.	0.6	22
117	Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Multiple Sclerosis Journal, 2013, 19, 941-946.	3.0	135
118	Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases. Journal of Immunology, 2013, 191, 3594-3604.	0.8	126
119	Role of Autoantibodies in Acquired Inflammatory Demyelinating Diseases of the Central Nervous System in Children. Neuropediatrics, 2013, 44, 297-301.	0.6	22
120	Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People. PLoS ONE, 2013, 8, e79649.	2.5	55
121	Antiâ€"Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients With Optic Neuritis. Archives of Neurology, 2012, 69, 752-6.	4.5	181
122	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Science, 2012, 10, 71.	1.7	22
123	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal, 2011, 17, 1067-1073.	3.0	144
124	Nogo-Receptors NgR1 and NgR2 Do Not Mediate Regulation of CD4 T Helper Responses and CNS Repair in Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2011, 6, e26341.	2.5	15
125	Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2011, 234, 124-130.	2.3	41
126	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 2011, 8, 184.	7.2	379

#	Article	IF	Citations
127	Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clinical Immunology, 2011, 138, 247-254.	3.2	180
128	Pathogenic T cell responses against aquaporin 4. Acta Neuropathologica, 2011, 122, 21-34.	7.7	81
129	Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages. BMC Research Notes, 2011, 4, 6.	1.4	20
130	Features of intrathecal immunoglobulins in patients with multiple sclerosis. Journal of the Neurological Sciences, 2010, 288, 147-150.	0.6	23
131	Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study. Journal of Neuroinflammation, 2010, 7, 79.	7.2	18
132	Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica. PLoS ONE, 2010, 5, e10455.	2.5	137
133	Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Annals of Neurology, 2009, 66, 630-643.	5.3	504
134	B Cells and Antibodies in MS. Results and Problems in Cell Differentiation, 2009, 51, 99-113.	0.7	7
135	Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis. PLoS ONE, 2008, 3, e2559.	2.5	113
136	Diagnostic biomarkers in multiple sclerosis. Expert Opinion on Medical Diagnostics, 2007, 1, 225-233.	1.6	4
137	Antimyelin Antibodies with No Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 426-428.	27.0	50
138	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology, 2007, 254, 160-168.	3.6	52
139	Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments. Journal of Neuroimmunology, 2006, 174, 147-156.	2.3	30
140	Antibodies as biological markers for pathophysiological processes in MS. Journal of Neuroimmunology, 2006, 180, 50-62.	2.3	69
141	Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event. New England Journal of Medicine, 2003, 349, 139-145.	27.0	589
142	Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis. Journal of Neuroimmunology, 2002, 131, 201-207.	2.3	17
143	Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain, 1999, 122, 2047-2056.	7.6	315